Abstract
Gelatinase B/MMP-9 fulfills crucial regulator or effector functions in disease states and may be pharmacologically targeted by specific inhibitors. The characteristics of cleavages of a natural gelatinase B substrate were simulated and amino acids with zinc-ion chelating side-groups were employed to design a library of peptide-based inhibitors. Here, we extend previous findings of combinatorial chemical synthesis and subsequent library deconvolution with a recently established high-throughput technology. This enabled us to study MMP inhibitors with two zinc-binding groups and to identify a new L-pyridylalanine-containing gelatinase B inhibitor. The peptide analog was found to inhibit, almost to the same degree, the neutrophil enzymes collagenase 2/ MMP-8 and MMP-9 and the monocytic tumor necrosis factor-β (TNF-β) converting enzyme (TACE/ADAM-17) in vitro and to protect mice against lethal endotoxinemia in vivo. These data illustrate the usefulness of the screening platform for protective inhibitor discovery and complement recent insights in the pathogenesis and treatment of shock syndromes.
Keywords: Matrix metalloproteinase, lipopolysaccharide, sepsis, inflammation, neutrophil, endotoxin
Combinatorial Chemistry & High Throughput Screening
Title: Inhibition of Lethal Endotoxin Shock with an L-Pyridylalanine Containing Metalloproteinase Inhibitor Selected by High-Throughput Screening of a New Peptide Library
Volume: 9 Issue: 8
Author(s): Christiane Dillen, Pierre Fiten, Patrick Chaltin, Jialiang Hu, Veronique Dubois, Philippe E. Van den Steen and Ghislain Opdenakker
Affiliation:
Keywords: Matrix metalloproteinase, lipopolysaccharide, sepsis, inflammation, neutrophil, endotoxin
Abstract: Gelatinase B/MMP-9 fulfills crucial regulator or effector functions in disease states and may be pharmacologically targeted by specific inhibitors. The characteristics of cleavages of a natural gelatinase B substrate were simulated and amino acids with zinc-ion chelating side-groups were employed to design a library of peptide-based inhibitors. Here, we extend previous findings of combinatorial chemical synthesis and subsequent library deconvolution with a recently established high-throughput technology. This enabled us to study MMP inhibitors with two zinc-binding groups and to identify a new L-pyridylalanine-containing gelatinase B inhibitor. The peptide analog was found to inhibit, almost to the same degree, the neutrophil enzymes collagenase 2/ MMP-8 and MMP-9 and the monocytic tumor necrosis factor-β (TNF-β) converting enzyme (TACE/ADAM-17) in vitro and to protect mice against lethal endotoxinemia in vivo. These data illustrate the usefulness of the screening platform for protective inhibitor discovery and complement recent insights in the pathogenesis and treatment of shock syndromes.
Export Options
About this article
Cite this article as:
Dillen Christiane, Fiten Pierre, Chaltin Patrick, Hu Jialiang, Dubois Veronique, Van den Steen E. Philippe and Opdenakker Ghislain, Inhibition of Lethal Endotoxin Shock with an L-Pyridylalanine Containing Metalloproteinase Inhibitor Selected by High-Throughput Screening of a New Peptide Library, Combinatorial Chemistry & High Throughput Screening 2006; 9 (8) . https://dx.doi.org/10.2174/138620706778249758
DOI https://dx.doi.org/10.2174/138620706778249758 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Does the Septic Shock Interfere Experimental Acute Pancreatitis in Rats?
Medicinal Chemistry The RNA Binding Protein HuR: a Promising Drug Target for Anticancer Therapy
Current Cancer Drug Targets Viral Gastroenteritis in Adults
Recent Patents on Anti-Infective Drug Discovery Current Treatment of Autoimmune Blistering Diseases
Current Drug Discovery Technologies Glutamate and Multiple Sclerosis
Current Medicinal Chemistry Prostratin: An Overview
Mini-Reviews in Medicinal Chemistry Metabolism and Pharmacological Mechanisms of Active Ingredients in <i>Erigeron breviscapus</i>
Current Drug Metabolism Tyrosine Kinases as Therapeutic Targets in BCR-ABL Negative Chronic Myeloproliferative Disorders
Current Drug Targets Moderate Wine Consumption in the Prevention of Metabolic Syndrome and its Related Medical Complications
Endocrine, Metabolic & Immune Disorders - Drug Targets Phylogenetic Methods in Drug Discovery
Current Drug Discovery Technologies Review of Erectile Dysfunction in Diabetic Animal Models
Current Diabetes Reviews Allergic and Pseudoallergic Reactions Induced by Glucocorticoids: A Review
Current Pharmaceutical Design Stereoselective Pharmacodynamics and Pharmacokinetics of Proton Pump Inhibitors
Current Drug Metabolism Gender Differences in Liver Fibrosis and Hepatitis C Virus-Related Parameters in Patients Coinfected with Human Immunodeficiency Virus
Current HIV Research Influence of Polymer Molecular Weight on in-vitro Characteristics and Cytotoxicity of Fulvestrant Loaded Nanoparticles
Current Drug Therapy Blood Coagulation as an Intrinsic Pathway for Proinflammation: A Mini Review
Inflammation & Allergy - Drug Targets (Discontinued) Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Association of Thrombospondin-1 (N700S) and Thrombospond in-4 (A387P) Gene Polymorphisms with the Incidence of Acute Myocardial Infarction in Egyptians
Current Pharmaceutical Biotechnology Piperine from Black Pepper Decreased the Expression of Intercellular Adhesion Molecule-1 in Macrophages
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Suppression of Protein Aggregation by L-Arginine
Current Pharmaceutical Biotechnology